Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
February 26, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
February 20, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines to Participate in Upcoming Investor Conferences
February 01, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
January 04, 2024 08:00 ET
|
Quanta Therapeutics, Inc.
QTX3034, G12D-preferring multi-KRAS inhibitor, IND received clearance by US FDA to begin Phase 1 study; planned for 1Q24; and other pipeline updates
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024 07:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
December 12, 2023 08:00 ET
|
Immuneering Corporation
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Revolution Medicines Completes Acquisition of EQRx
November 09, 2023 09:10 ET
|
Revolution Medicines, Inc.
Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning,...
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
November 08, 2023 11:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for...
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
November 06, 2023 16:05 ET
|
Revolution Medicines, Inc.
Promising clinical data for RMC-6236, a RASMULTI(ON) Inhibitor, and RMC-6291, a RASG12C(ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings Acquisition of EQRx, Inc. expected to...
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
October 31, 2023 16:15 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...